Redeye comments on Cantargia's Q1 report. The main thing that stands out is the great Q/Q cost reduction. There has also been developments in inflammatory diseases relevant for CAN10.
ANNONS
Redeye comments on Cantargia's Q1 report. The main thing that stands out is the great Q/Q cost reduction. There has also been developments in inflammatory diseases relevant for CAN10.